Merck and Ridgeback submit EUA application for tablets to treat COVID-19

Date:

Merck & Co. Inc.
MRK,
-1.60%

Ridgeback Biotherapeutics said Monday that Merck submitted an Emergency Use Authorization (EUA) application to the Food and Drug Administration of Molnupiravir, an oral antiviral drug for the treatment of mild to moderate COVID-19 in adults. .. The two companies said the application followed the positive results of a phase 3 trial showing that molnupiravir reduces the risk of hospitalization or death by 50% in adults at risk of developing severe COVID-19. Said. According to the two companies, 7.3% (28/385) of patients who received molnupiravir were hospitalized and did not die 29 days later, but 14.1% (53/377) of patients treated with placebo. Was hospitalized and eight people died. Robert Davis, Merck’s Chief Executive Officer, said:Merck’s share price, which fell 1.2% in pre-market trading, rose 3.4% year-to-date, but the Dow Jones Industrial Average averaged 30 stocks.
DJIA,
-0.03%

It is 13.5% ahead.

Merck and Ridgeback submit EUA application for tablets to treat COVID-19

Source link Merck and Ridgeback submit EUA application for tablets to treat COVID-19

The post Merck and Ridgeback submit EUA application for tablets to treat COVID-19 appeared first on Eminetra.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Popular

More like this
Related